Plant Derived Proteins Market to Surge to USD 272.1 Million by 2035 Driven by Therapeutics and Sustainability

The global plant derived proteins market is witnessing unprecedented growth, driven by rising demand for sustainable, eco-friendly, and high-quality protein sources across food, pharmaceutical, and industrial sectors. Estimated at USD 130.8 million in 2025, the market is projected to reach USD 272.1 million by 2035, registering a robust compound annual growth rate of 7.6%. This expansion reflects an increasing consumer and industry preference for plant-based alternatives, propelled by technological innovation, regulatory support, and shifting societal values toward environmental sustainability.

Established players like Medicago Inc., Planet Biotechnology Inc., and Kentucky Bioprocessing, LLC are setting benchmarks with cutting-edge research and commercialization strategies, while emerging companies such as Agrenvec and Axol Bioscience Ltd are exploring new platforms and production methods to capture niche segments in therapeutics, functional proteins, and biopolymers.

Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-11038

Driving Factors: Sustainability Meets Biopharmaceutical Innovation

Rising consumer awareness about health and environmental impacts has fueled the demand for plant-based proteins. Biotechnology advancements and improved agricultural practices have enabled enhanced extraction and processing methods, resulting in higher protein quality and yield. The growing popularity of protein biopolymers, therapeutic proteins, and cell culture functional proteins underscores the industry’s move toward multifunctional, eco-friendly applications.

Increasing investments in research and development have enabled the creation of novel proteins with tailored functional properties. Regulatory encouragement and public interest in reducing reliance on animal-derived proteins have further supported market expansion, while platforms such as in-vitro culture systems allow for controlled, scalable, and consistent protein production.

Segmental Insights: Tobacco, Protein Biopolymers, and In-Vitro Culture Systems

Among plant types, tobacco stands out as a leading contributor, expected to account for 19.4% of the market revenue in 2025. Its fast growth cycle, high protein content, and adaptability to various climates make it an ideal candidate for scalable protein production. Advances in molecular farming and plant modification techniques have allowed tobacco to produce proteins tailored for pharmaceutical and industrial use, from therapeutic antibodies to functional biopolymers.

Protein biopolymers dominate the protein type category, projected to generate 28.1% of market revenue in 2025. These versatile biopolymers are increasingly adopted in biodegradable packaging, medical materials, and sustainable industrial applications. Continuous improvements in extraction and processing methods have enhanced their performance, supporting the shift from conventional synthetic polymers to eco-friendly, protein-based alternatives.

The in-vitro culture system segment leads the platform category, representing 34.7% of market revenue in 2025. By providing controlled environments for consistent protein production, these systems minimize dependency on climatic factors and land usage, offering high scalability and purity. Additionally, in-vitro platforms enable the production of proteins that are otherwise difficult to extract from whole plants, opening new opportunities in biopharmaceutical and regenerative medicine applications.

Market Evolution: Trends, Drivers, and Regulatory Dynamics

From 2020 to 2025, plant derived proteins recorded steady growth, benefiting from increasing adoption in regenerative medicine, cosmetics, and industrial applications. However, market dynamics are influenced by regulatory frameworks, pricing fluctuations, and consumer trends, including gluten- and soy-free diets that have slightly affected short-term adoption. Despite these challenges, therapeutic applications, particularly in monoclonal antibodies, vaccines, and recombinant proteins, are creating strong growth momentum.

The market’s growth trajectory is further bolstered by the rising prevalence of chronic diseases such as diabetes, hepatitis, cancer, and Gaucher disease. Traditional microbial and mammalian platforms for biologics often face limitations in cost, scalability, and eukaryotic protein modifications. Plant-derived proteins offer a sustainable, scalable, and cost-effective alternative, allowing companies to meet the growing demand for therapeutics, including insulin, albumin, and novel antibodies.

Regional Growth Outlook

North America, Europe, and Asia-Pacific emerge as key growth regions. In the USA, rapid adoption is driven by innovations in novel therapeutics and biologics, with companies such as iBio, Inc. leveraging advanced FastPharming technologies to develop new plant-based biologics. These innovations, including IBIO-100, IBIO-200, and IBIO-201, underscore the country’s leadership in integrating plant-derived proteins into pharmaceutical pipelines.

India is poised to become the most lucrative market in South Asia between 2025 and 2035. The increasing burden of lifestyle diseases such as diabetes, coupled with a growing biotechnology sector, drives demand for plant-derived recombinant proteins, including insulin. Rapid urbanization, improved healthcare infrastructure, and government-backed R&D initiatives further support this expansion.

The UK demonstrates strong growth potential, largely fueled by the cosmetic industry’s shift toward plant-based ingredients. With consumers seeking natural and sustainable options, plant-derived proteins are increasingly incorporated into skincare, serums, and other cosmetic products, providing both efficacy and environmental benefits.

Therapeutic Proteins and Regenerative Medicine: Key Growth Areas

Therapeutic proteins are projected to account for more than 70% of sales from 2025 to 2035. The rising demand for monoclonal antibodies, vaccines, and regenerative medicine agents is driving this segment. Plant-derived proteins offer advantages such as rapid scalability, low cost, and effective eukaryotic modifications, enabling faster and more reliable production of advanced biologics.

In regenerative medicine, plant-derived scaffold proteins are gaining prominence as functional materials for cell adhesion, proliferation, and biomatrix formation. These proteins support tissue engineering, drug screening, and clinical research, underscoring the sector’s potential to transform medical therapeutics.

Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/brochure/rep-gb-11038

End Users and Industrial Applications

Biopharmaceutical companies remain the largest end-users, accounting for over 50% of the market demand by 2035. Increasing R&D investment, coupled with government support, is fostering the development of novel therapeutics and plant-based biologics. Academic and research institutes, contract research organizations, and contract manufacturing organizations are also leveraging plant-derived proteins for experimental studies, drug development, and large-scale production.

Industrial applications extend beyond pharmaceuticals into biodegradable materials, functional biopolymers, and environmentally-friendly alternatives to synthetic proteins, further expanding market opportunities.

Competitive Landscape: Innovation and Expansion

The plant-derived proteins market is characterized by a mix of established biotechnology firms and innovative newcomers. Medicago Inc., Planet Biotechnology Inc., Kentucky Bioprocessing, LLC, Ventria Bioscience, and Icon Genetics lead the market with established portfolios and global distribution networks. Emerging players such as Agrenvec, Axol Bioscience Ltd, and PromoCell GmbH are leveraging novel platforms, including in-vitro culture systems and advanced glycoengineering techniques, to differentiate their offerings.

Strategic expansions, collaborations, mergers, and product launches are key strategies among market participants. For instance, in April 2024, Protalix BioTherapeutics, Inc., an Israeli-based company, received a Complete Response Letter from the FDA for its pegunigalsidase alfa (PRX–102), a recombinant alpha-Galactosidase-A protein, highlighting regulatory milestones and innovation pipelines in plant-derived therapeutics.

Related Reports:

Meningococcal Vaccines Market: https://www.futuremarketinsights.com/reports/meningococcal-vaccines-market

Orthokeratology Market: https://www.futuremarketinsights.com/reports/orthokeratology-market

Whole Genome Amplification Market: https://www.futuremarketinsights.com/reports/whole-genome-amplification-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:     

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs | YouTube